Aytu BioScience closes on $5.175M note financing

Aytu BioScience closes on $5.175M note financing

ENGLEWOOD-- Aytu BioScience Inc . (OTCQB: AYTU), a specialty health care company focused on developing treatments for urological and related conditions, announced it has closed on the final... Read More

Thursday September 3, 2015 0 comments Tags: Englewood, Aytu BioScience, Josh Disbrow, Zertane, RedoxSYS, ProstaScint

Aytu to acquire rights to Jazz Pharmaceuticals’ ProstaScint prostate detection drug

Aytu to acquire rights to Jazz Pharmaceuticals’ ProstaScint prostate detection drug

ENGLEWOOD-- Aytu BioScience Inc. (OTCMKTS: RSWN), a specialty health care company focused on developing treatments for urological and related conditions, today announced it entered into an... Read More

By: InnovatioNews Tuesday June 9, 2015 0 comments Tags: Englewood, Aytu BioScience, Jazz Pharmaceuticals, Josh Disbrow, ProstaScint, Zertane, RedoxSYS

Ampio's Vyrix signs agreement with Canada-based Paladin Labs to market Zertane

Ampio's Vyrix signs agreement with Canada-based Paladin Labs to market Zertane

GREENWOOD VILLAGE - Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE) today announced its wholly-owned subsidiary, Vyrix Pharmaceuticals , has signed an agreement with Quebec, Canada-based  Paladin... Read More

By: InnovatioNews Thursday April 10, 2014 0 comments Tags: Greenwood Village, Jarrett Disbrow, Paladin Labs, Zertane